தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு Today - Breaking & Trending Today

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
News provided by
Share this article
Share this article
NEWTON, Mass., May 19, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2021.
Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company s first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) multiple new subgroup analyses from the pivotal Phase 3 BOSTON study, including data results evaluating XPOVIO treatment for patients over the age of 65 years old and patients with RAS-mutated mul ....

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , University Hospital , Xavier Leleu , Christopherj Walker , Mike Dolph , Talia Golan , Shannon Westin , Sangmin Lee , Yasaman Demastani , Cesar Serrano , Darrell White , Cristina Gasparetto , Thierry Facon , Yazmin Odia , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Virginia University School Of Medicine Neurology Neurosurgery , American Society Of Clinical Oncology , Weill Cornell Medical College , Selective Inhibitor Of Nuclear , University Hospitals Leuven , Leuven Cancer Institute , Miami Cancer Institute , Karyopharm Selective Inhibitor Of Nuclear Export , Mcgill University , Information Department ,

Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

Share this article
Share this article
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (rrMM) in China.
The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and dexamethasone (SVd) regimen against bortezomib and dexamethasone (Vd) regimen in Chinese adult patients with rrMM who have received one to thr ....

United States , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Antengene Corporation , Drug Administration , Selective Inhibitor Of Nuclear , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Corporation Limited , Investigational New Drug , Selective Inhibitor , Nuclear Export , Clinical Practice Guidelines , Karyopharm Therapeutics , Safety Monitoring Board , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஜெய் மெய் , ஆசியா பெஸிஃபிக் , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு , இணைப்பு திசு புற்றுநோயியல் சமூகம் ,